Full-Time
Posted on 8/20/2026
Global asset management for institutional clients
No salary listed
London, UK
Hybrid
Four days per week in the office; one day per week may be worked remotely.
See people who can refer or advise you
Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$64.9B
Headquarters
Boston, Massachusetts
Founded
1933
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health coverage
Work-life balance
Financial future
Development
Muon Space closed a $250M Series C led by Eclipse Capital and joined by Google & Salesforce Ventures to scale constellation production....
Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.
The $545 million Series G nearly doubles Whatnot's valuation—a rare consumer-marketplace breakout at a moment when nearly every venture dollar is flowing to AI.
Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.
Wellington Management has launched two closed-end funds in partnership with Vanguard and Blackstone, initially available through Bank of America's wealth platforms. The WVB All Markets Fund combines public equities, fixed income, index strategies and Blackstone's private-market assets. The WVB Blackstone All Privates Fund allocates across private equity, infrastructure, real estate and credit. Both funds will be offered to eligible clients of Merrill and Bank of America Private Bank, with plans to expand through registered investment advisers and other wealth channels. Wellington serves as investment manager, whilst Vanguard provides fixed-income and index exposure and Blackstone contributes its perpetual private-market platform. The launch reflects broader efforts to bring private-market investments, traditionally limited to institutions, to high-net-worth and mass-affluent investors.